Medtronic Avila(TM) Interbody Fusion Device Launched in Europe

Tolochenaz, Switzerland (ots/PRNewswire) -

European innovation delivers titanium family of cages to support
twin surgical objectives of bone fusion and sagittal realignment for
improved patients' outcomes.

Medtronic PLC (NYSE: MDT), the global leader in medical
technology, today announced the launch of AVILA(TM), its new family
of interbody fusion devices for L2-S1 levels in open and minimally
invasive ALIF and OLIF procedures.

(Logo: http://photos.prnewswire.com/prnh/20160307/340988LOGO )

(Logo: http://photos.prnewswire.com/prnh/20160307/340989LOGO )

AVILA(TM) addresses the multiple needs of interbody fusion
procedures with its smart cage design. A wide range of lordotic
options up to 24° and an anatomical shape provide the support to
realign the spine. Titanium alloy properties are combined with large
inner and lateral windows for bone grafting and post-operative fusion
assessment.

Dr. Frank Hassel, orthopaedic surgeon at Loretto-Krankenhaus
Hospital in Freiburg, Germany, commented after his first surgery with
AVILA(TM): "AVILA(TM) is straightforward to use, which eases even
complex surgeries. I like the strong connection between cage and
inserter during the impaction. I was able to adequately correct the
lordosis and place a large amount of bone graft. These are necessary
aspects to improve fusion and stability outcomes."

AVILA(TM) is provided in a compact kit with a unique dismountable
inserter, allowing for easier sterilisation, making operating room
management faster and reducing the time and cost of surgery.

Sharrolyn Transfeldt Josse, Medtronic Vice-President Spine & Pain
Europe, remarked: "AVILA(TM) exists as a result of our collaboration
with surgeons, for whom the goals of spinal surgery are increasingly
two-fold; achieve fusion and restore sagittal alignment. AVILA(TM)
addresses those objectives, and we are proud this product was
conceived and developed entirely at our Product Development Office in
Switzerland."

AVILA(TM) is the newest addition to Medtronic spinal portfolio,
and it integrates with PYRAMID®+4 Anterior Lumbar Plate System,
posterior fixation systems such as CD HORIZON® LONGITUDE® II and with
the extensive biologic portfolio including Grafton® Demineralized
Bone Matrix and Mastergraft®.

AVILA(TM) interbody fusion devices have CE-Mark for use for
interbody fusion with autogenous bone graft and/or bone graft
substitute in adults with degenerative disc disease (DDD) at one or
two contiguous levels from L2 to S1. Eligible patients must have had
at least six months of non-operative treatment for this condition.
These DDD patients may also have up to Grade 1 spondylolisthesis or
retrolisthesis at the involved levels. These devices are intended for
use with supplemental fixation instrumentation, which has been
cleared for use in the lumbar spine.

AVILA(TM) family of interbody fusion devices incorporates
technology developed by Gary K. Michelson, M.D.

About the Spinal Business at Medtronic

Medtronic's Spinal business, based in Memphis, Tenn., is the
global leader in today's spine market and is committed to advancing
the treatment of spinal conditions. Medtronic's Spinal business
collaborates with world-renowned surgeons, researchers and innovative
partners to offer state-of-the-art therapies for spinal,
neurological, orthopaedic and oral maxillofacial conditions.
Medtronic is committed to developing affordable, minimally invasive
procedures that provide lifestyle friendly surgical therapies. More
information about Spinal's therapies can be found at the business
unit's patient education website, http://www.back.com

About Medtronic

Medtronic plc (http://www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 85,000 people worldwide, serving physicians,
hospitals and patients in more than 160 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.

Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic reports
on file with the Securities and Exchange Commission. Actual results
may differ materially from anticipated results.

AVILA(TM) is CE Marked. AVILA(TM) is not approved in jurisdictions
which do not recognize the CE Mark.

Contacts :

Valerie Courcier Media Relations +33-1-55-38-17-36

Linda Pavy Linda.pavy@bm.com PR Agency +33-6-07-59-43-95

ots Originaltext: Medtronic
Im Internet recherchierbar: http://www.presseportal.de